# ILiAD Biotechnologies

> ILiAD Biotechnologies, Inc. is a privately held, clinical-stage biotechnology company headquartered in Weston, Florida, developing BPZE1 — a live attenuated intranasal vaccine candidate designed to prevent Bordetella pertussis (whooping cough) colonization and transmission — and the B-Tech™ Vector Platform it is built on. ILiAD publishes **no API, SDK, developer portal, or machine-readable specification**. This file is generated by API Evangelist from ILiAD's public website; it is not published by ILiAD Biotechnologies.

<!--
generated: '2026-08-22'
method: generated
source: apis.yml + https://iliadbio.com/ (searched https://iliadbio.com/llms.txt -> HTTP 404)
-->

## APIs

- No public API surface. On iliadbio.com, `/openapi.json`, `/openapi.yaml`, `/swagger.json`, `/v1/openapi.json`, `/api-docs`, `/api`, `/docs`, `/redoc`, `/graphql`, `/llms.txt` and every probed `/.well-known/*` path (security.txt, openid-configuration, oauth-authorization-server, oauth-protected-resource, api-catalog, ai-plugin.json, agent-card.json, agent.json) return a real HTTP 404; the same paths 404 on iliadbiotech.com. `api.`, `docs.`, `developer.`, `portal.`, `app.`, `status.` and `trust.iliadbio.com` do not resolve in DNS (checked 2026-08-22).
- The site is static HTML: 88 URLs in its sitemap, of which roughly half are patent-certificate and publication PDFs. `robots.txt` disallows only `/corp/`.

## Science

- [BPZE1 Vaccine](https://iliadbio.com/our_science/bpze1_vaccine.html): Lead candidate — a live attenuated intranasal pertussis vaccine, licensed exclusively from Institut Pasteur de Lille, intended to prevent B. pertussis colonization and onward transmission rather than only disease.
- [Why a Live Vaccine?](https://iliadbio.com/our_science/why-live-vaccine.html)
- [Preventing Colonization + Transmission](https://iliadbio.com/our_science/preventing_colonization_transmission.html)
- [Preclinical Safety](https://iliadbio.com/our_science/preclinical_safety.html)
- [BPZE1 Publications](https://iliadbio.com/our_science/publications.html)
- [Clinical](https://iliadbio.com/clinical.html)
- [Pipeline](https://iliadbio.com/opportunity/pipeline.html)
- [Intellectual Property](https://iliadbio.com/opportunity/intellectual-property.html)

## Company

- [Website](https://iliadbio.com/)
- [Overview](https://iliadbio.com/company/overview.html)
- [For Investors](https://iliadbio.com/company/for-investors.html)
- [News](https://iliadbio.com/company/news.html)
- [Executive Board](https://iliadbio.com/team/executive-board.html)
- [Management Team](https://iliadbio.com/team/management-team.html)
- [Scientific Advisory Board](https://iliadbio.com/team/scientific-advisory-board.html)
- [Careers](https://iliadbio.com/careers.html)
- [Contact](https://iliadbio.com/contact-us.html)
- [Privacy Policy](https://iliadbio.com/privacy-policy.html)

## Artifacts

- [Domain security probe](https://raw.githubusercontent.com/api-evangelist/iliad-biotechnologies/refs/heads/main/security/iliad-biotechnologies-domain-security.yml): TLS/HSTS/DNSSEC/CAA/SPF/DMARC posture for iliadbio.com and iliadbiotech.com, probed by API Evangelist.
- [Well-known probe](https://raw.githubusercontent.com/api-evangelist/iliad-biotechnologies/refs/heads/main/well-known/iliad-biotechnologies-well-known.yml): the measured absence of every `/.well-known/` discovery document on both hosts, with soft-404 control probes.